ENANTA PHARMACEUTICALS INC (ENTA)
US29251M1062 - Common Stock
ENTA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. The financial health of ENTA is average, but there are quite some concerns on its profitability. ENTA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ENTA had negative earnings in the past year.
In the past year ENTA has reported a negative cash flow from operations.
ENTA had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ENTA reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of ENTA (-32.26%) is better than 69.80% of its industry peers.
ENTA has a Return On Equity of -72.05%. This is comparable to the rest of the industry: ENTA outperforms 55.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.26% | ||
| ROE | -72.05% | ||
| ROIC | N/A |
ROA(3y)-26.46%
ROA(5y)-15.47%
ROE(3y)-39.81%
ROE(5y)-23.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ENTA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ENTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ENTA has more shares outstanding
Compared to 5 years ago, ENTA has more shares outstanding
The debt/assets ratio for ENTA has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.13, we must say that ENTA is in the distress zone and has some risk of bankruptcy.
ENTA has a Altman-Z score (-0.13) which is in line with its industry peers.
ENTA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ENTA's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. ENTA outperforms 46.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.13 |
ROIC/WACCN/A
WACC9.28%
2.3 Liquidity
A Current Ratio of 6.25 indicates that ENTA has no problem at all paying its short term obligations.
The Current ratio of ENTA (6.25) is better than 63.99% of its industry peers.
A Quick Ratio of 6.25 indicates that ENTA has no problem at all paying its short term obligations.
ENTA's Quick ratio of 6.25 is fine compared to the rest of the industry. ENTA outperforms 64.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.25 | ||
| Quick Ratio | 6.25 |
3. Growth
3.1 Past
The earnings per share for ENTA have decreased strongly by -12.71% in the last year.
Looking at the last year, ENTA shows a very negative growth in Revenue. The Revenue has decreased by -10.34% in the last year.
The Revenue for ENTA have been decreasing by -17.45% on average. This is quite bad
EPS 1Y (TTM)-12.71%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-13.67%
Revenue 1Y (TTM)-10.34%
Revenue growth 3Y-13.53%
Revenue growth 5Y-17.45%
Revenue growth Q2Q-23.68%
3.2 Future
Based on estimates for the next years, ENTA will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.55% on average per year.
ENTA is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.68% yearly.
EPS Next Y18.53%
EPS Next 2Y11.89%
EPS Next 3Y10.55%
EPS Next 5Y8.55%
Revenue Next Year-12.63%
Revenue Next 2Y-1.75%
Revenue Next 3Y-1.1%
Revenue Next 5Y-1.68%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ENTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENTA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.89%
EPS Next 3Y10.55%
5. Dividend
5.1 Amount
No dividends for ENTA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ENANTA PHARMACEUTICALS INC
NASDAQ:ENTA (4/26/2024, 7:00:02 PM)
After market: 12.37 0 (0%)12.37
-0.11 (-0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap261.75M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.26% | ||
| ROE | -72.05% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.25 | ||
| Quick Ratio | 6.25 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-12.71%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y18.53%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-10.34%
Revenue growth 3Y-13.53%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y